MARKET INSIGHT: Insulin delivery techs and the role of long-term cost structures
This article was originally published in Clinica
Executive Summary
Uptake of insulin pump therapy varies sharply from market to market. In the US, over a third of Type I diabetics use a pump, but in Europe this can be as low as the mid-single digits. The speed of new technology roll-outs can be affected by the previous therapy policy of any particular country, but are stakeholders doing enough to ensure that more eligible individuals can access this proven delivery means? IBI principal analyst Ashley Yeo investigates